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A number of antimycobacterial agents were evaluated with respect to their bacteriostatic activity (growth
inhibition) versus the bactericidal activity against a clinical isolate of Mycobacterium avium (Mycobacterium
avium complex [MAC] strain 101) in relation to the time of exposure and the growth phase of the mycobacteria.
In terms of growth inhibition the MAC in the active phase of growth was susceptible to clarithromycin,
ethambutol, rifampin, amikacin, and the quinolones moxifloxacin, ciprofloxacin, and sparfloxacin. In terms of
bactericidal activity in relation to the time of exposure these agents differed substantially with respect to the
killing rate. An initial high killing capacity at low concentration was observed for amikacin, which in this
respect was superior to the other agents. The bactericidal activity of clarithromycin and ethambutol was only
seen at relatively high concentrations and increased with time. Killing by rifampin was concentration depen-
dent as well as time dependent. The bactericidal activity of moxifloxacin was marginally dependent on the
concentration or the time of exposure. The activity of clarithromycin in combination with ethambutol was not
significantly enhanced compared to single-agent exposure. Only an additive effect was observed. The addition
of rifampin or moxifloxacin as a third agent only marginally effected increased killing of MAC. However, by
addition of amikacin the activity of the clarithromycin-ethambutol combination was significantly improved.
The combination of amikacin and amoxicillin-clavulanic acid exhibited synergistic antimycobacterial activity.
Towards MAC at low growth rates, only the quinolones exhibited a bactericidal effect.
Mycobacterial infections (tuberculosis and atypical myco-
bacterial infections) continue to cause immense morbidity and
mortality, particularly in developing countries, and there is
clear evidence that the incidence of (multidrug-resistant) my-
cobacterial infections is increasing (10, 16, 42, 43). The treat-
ment of mycobacterial infections is complicated (12, 39). The
intracellular location and the quiescent character of the per-
sistent mycobacteria result in decreased efficacy of antimyco-
bacterial agents (18). Therefore treatment must be continued
for months to years. It is generally accepted that long-term
exposure of mycobacteria to suboptimal concentrations of an-
timycobacterial agents facilitates the selection of resistant mu-
tants. Combinations of antimycobacterial agents are used to
minimize the emergence of antimicrobial resistance.
Whereas for tuberculosis susceptibility testing is extremely
important in guiding treatment (51), for Mycobacterium avium
complex (MAC) infections a predictable relationship between
in vitro susceptibility testing and clinical utility of agents for
therapy is marginal (46). The range of susceptibilities of MAC
isolates to most antimycobacterial agents, except for macro-
lides, is very broad (25, 26, 29). There are no controlled clinical
trials demonstrating a correlation between in vitro susceptibil-
ity tests for MAC and clinical response. A number of studies
reviewed by Shafran et al. (46) examining the role of in vitro
susceptibilities in predicting the clinical outcome of drug treat-
ment of MAC infection are available but show contradictory
results.
Several techniques are applied to determine the antimicro-
bial susceptibility of mycobacteria in vitro (2, 24, 26, 29). Pref-
erably quantitative assays such as the agar dilution method are
used. Heifets suggested giving preference to methods of broth-
determined MICs (22). The radiometric BACTEC macrodilu-
tion method (radiometric detection of growth) produces a
quantitative endpoint in terms of an MIC which can be corre-
lated with the drug concentration attainable in humans (26, 3).
For MAC National Committee of Clinical Laboratory Stan-
dards (35) are only available for in vitro testing of susceptibility
to macrolides because of the correlation between this test and
clinical response. Heifets and Iseman recommend susceptibil-
ity testing of the patient’s isolate, which can serve for better
selection of drugs for an individualized treatment regimen
(27).
The interpretation of the data of antimicrobial susceptibility
of mycobacterial strains in vitro is difficult. Mostly the results of
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the susceptibility tests are red at the end of the incubation
period. This in vitro approach does not reflect the in vivo
events, as exposure of mycobacteria to maximum achievable
concentrations in vivo last for only a short period. In addition,
often inhibition of mycobacterial growth is assessed. As stated
by the National Committee for Clinical Laboratory Standards
(NCCLS), in antimicrobial susceptibility methods a time factor
should be included. The rate of killing may have more clinical
significance than the degree of killing. However, the antimi-
crobial killing rate in relation to the time of exposure is also an
important characteristic for therapeutic efficacy in the patients
with mycobacterial infections. The ideal antimycobacterial
agent should exhibit a high killing capacity resulting in a rapid
decrease in bacterial load, and hence a reduced risk of devel-
opment of resistance. Also substantial activity of the agents
against mycobacteria at low growth rate is an important deter-
minant. At the site of infection mycobacteria are often local-
ized intracellularly, and their metabolic activity intracellularly
is extremely low.
The present study was undertaken to assess the bacteriosta-
tic activity (growth inhibition) versus the bactericidal activity of
a number of antimycobacterial agents at various concentra-
tions against a clinical isolate of MAC in relation to the time of
exposure. MAC strain 101 serotype 1, one of the three most
common serotypes isolated from patients with AIDS (54) was
used. In addition, the antimicrobial activity in relation to the
bacterial growth rate was investigated. To that aim mycobac-
teria in the active phase of growth (early logarithmic phase)
were exposed to antimycobacterial agents, as well as mycobac-
teria at the end of the active growth phase (late logarithmic
phase) to simulate low metabolic activity of mycobacteria.
Agents from various classes of antimicrobials available for the
treatment of MAC infections including the macrolide clar-
ithromycin (CLR) as a first-line drug (11, 45) are involved in
the study. As macrolide-containing multidrug regimens are
often used in the treatment of MAC infection (13, 45, 9, 28, 15,
48, 3, 6), also combinations of CLR with various agents were
evaluated. In this regard the potential of fluoroquinolones or
aminoglycosides was investigated. In addition, the activity of an
aminoglycoside-beta-lactam combination was examined.
MATERIALS AND METHODS
Organism. The Mycobacterium avium strain used in this study was MAC strain
101 (serovar 1), originally isolated from the blood of an AIDS patient with
disseminated MAC infection, and was kindly supplied by L. S. Young, Kuzell
Institute for Arthritis and Infectious Diseases, San Francisco, CA. MAC organ-
isms were cultured on Middlebrook 7H10 agar medium (Difco Laboratories,
Detroit, MI) supplemented with oleic acid-albumin-dextrose-catalase enrich-
ment (OADC; Baltimore Biological Laboratories, Baltimore, MD) for 14 days at
37°C. MAC suspensions were prepared in Middlebrook 7H9 broth (Difco) sup-
plemented with OADC and stored at 80°C.
Antimycobacterial agents. Clarithromycin (CLR) was obtained from Abbott
(Saint Remy, France); ethambutol (EMB), amikacin (AMK), streptomycin
(STR), isoniazid (INH) and pyrazinamide (PZA) were purchased from Sigma
Chemical Co. (St. Louis, MO); ciprofloxacin (CIP) and moxifloxacin (MXF)
were obtained from Bayer (Leverkusen, Germany); tobramycin (TOB) and gen-
tamicin (GEN) was purchased from Centrafarm (Etten-Leur, The Netherlands);
sparfloxacin (SPX) was obtained from Rhone Poulenc Rorer (Vitry sur Seine
Cedex, France); rifampin (RIF) was obtained from Hoechst Marion Roussel
(Hoevelaken, The Netherlands); and amoxicillin-clavulanic acid (AMC) was
obtained from GlaxoSmithKline B.V. (Zeist, The Netherlands). Dilutions of
antimicrobial agents were prepared according to the recommendations of the
manifacturers.
Susceptibility testing. Drug susceptibility of the MAC strain in terms of MIC
was performed using a broth-based method (macrodilution) according to the
guidelines of the National Committee for Clinical Laboratory Standards
(NCCLS) M24-T2 using 7H9 broth supplemented with OADC, pH 6.8 (35).
Antibiotic concentrations ranged from 0.1 to 64 mg/liter (doubling dilutions) for
all agents, and 128 and 256 mg/liter for CLR only. The inoculum was prepared
from a fresh broth culture and was finally 1.5  105 CFU/ml as confirmed by
quantitative plate counts. Tubes containing 4 ml were incubated at 37°C and
examined at 14 days. The MIC was determined as the lowest concentration that
inhibited visible growth.
Time-kill studies. The MAC inocula in the early logarithmic phase of growth
or late logarithmic phase of growth were prepared in 7H9 broth supplemented
with OADC under shaking conditions at 93 rpm. Early-log-phase MAC inocula
at 5  105 CFU/ml and late-log-phase MAC inocula of 1.1  109 CFU/ml were
exposed to the antimycobacterial agent at twofold increasing concentrations
(range, 0.05 to 64 mg/liter) for 21 days at 37°C. In 60-ml flasks 20 ml of bacterial
suspensions were incubated under shaking conditions at 93 rpm. The initially
clear suspensions of early-log-phase MAC inocula allowed establishment of a
bacteriostatic as well as a bactericidal effect of the antimicrobial agents. A
bacteriostatic effect was expressed as the lowest concentration that inhibited
visible growth at day 21. When a bactericidal effect was observed the killing
capacity of the agent was expressed as the lowest concentration that resulted in
99% killing at day 3, 10, or 21. According to the NCCLS, there are no
guidelines available to determine MBC for mycobacteria. Although the inter-
pretive criteria of bactericidal activity of antimycobacterial agents are not uni-
form, in the majority of studies the MBC designated for mycobacteria is defined
as the minimal concentration effectively reducing the bacterial counts by 99%.
For the late-log-phase MAC inocula which are not clear suspensions only a
bactericidal effect of the agents could be determined. To determine the bacte-
ricidal effect after 1, 2, 3, 10, and 21 days of exposure quantitative cultures were
performed as follows. The bacterial suspensions were centrifuged at 2400 g for
10 min, washed in 7H9 broth supplemented with OADC and centrifuged again.
Samples were serially diluted and plated onto 7H10 agar supplemented with
OADC. After 14 days of incubation at 37°C CFU numbers were counted. In the
studies where MAC was exposed to combinations of agents quantitative cultures
were performed after 3 and 10 days of incubation.
RESULTS
Susceptibility according to NCCLS. The broth-determined
MIC of CLR for the MAC strain 101 at pH 6.8, defined as the
lowest concentration that inhibited visible growth, was 4 mg/
liter. Interpretation of this MIC according to the interpretive
criteria (breakpoints) mentioned in the NCCLS M24-T2 doc-
ument and based, in part, on a monotherapy trial of dissemi-
nated disease in humans is that MAC strain 101 is susceptible
to CLR.
The MIC for EMB and RIF was 16 mg/liter and 4 mg/liter,
respectively. For the aminoglycosides AMK and STR the MIC
was 1 mg/liter and 16 mg/liter, respectively. For the quinolones
MXF, CIP, and SPX the MIC was 0.1 mg/liter, 0.25 mg/liter,
and 0.25 mg/liter, respectively.
Time-kill studies in relation to the mycobacterial growth
phase. In the absence of antimicrobial agent inocula of MAC
in the early log phase of growth increased from 5.0  105
CFU/ml (day 0) to 6.0  107 CFU/ml, 2.0  109 CFU/ml, and
1.9  109 CFU/ml at day 3, day 10, and day 21, respectively.
MAC in the late log phase of growth increased from 1.1  109
CFU/ml (day 0) to 2.0  109 CFU/ml, 2.2  109 CFU/ml, and
2.1  109 CFU/ml at day 3, day 10, and day 21, respectively.
For five agents representative of the various classes of antimi-
crobials relevant in the treatment of MAC being CLR, EMB,
RIF, AMK, and MXF, the data obtained at all concentrations
tested are shown in Fig. 1 to 5. Calculation of the data for these
agents and all other agents studied are summarized in Table 1.
To clearly gauge the concentration-dependent versus time-
2388 BAKKER-WOUDENBERG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
FIG. 1. Mycobacterium avium strain 101 in the early logarithmic phase of growth was exposed to clarithromycin at twofold increasing
concentrations for 21 days at 37°C. After 1, 2, 3, 10 or 21 days of exposure quantitative cultures were performed.
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dependent effects, the data obtained for MAC in the early log
phase of growth have been presented as viable count versus
time at all concentrations tested (panels A in all figures) and as
viable count versus concentration at all days assessed (panels B
in all figures).
Exposure of early-log-phase MAC to CLR resulted in a
concentration-dependent as well as time-dependent effect
(Fig. 1A and B, Table 1). The lowest concentration of CLR
effecting complete inhibition of growth was 4 mg/liter. At con-
centrations of 8 mg/liter or higher MAC organisms were killed,
and 99% reduction of the inoculum was obtained after ex-
posure to 16 mg/liter CLR for 10 days. A maximum bacteri-
cidal effect was obtained at the relatively high concentration of
256 mg/liter. Substantial killing by CLR was not observed when
MAC was in the late log phase of growth. At the relatively high
concentration of 64 mg/liter about 87% of the MAC popula-
tion was killed after 10 days of incubation, and bacterial num-
bers did not further decrease. At the concentrations tested
99% killing of the inoculum was never achieved (data not
shown).
EMB also showed killing of MAC in the early log phase of
growth which effect was primarily time-dependent (Fig. 2A and
B, Table 1). Inhibition of visible growth was obtained at 16
mg/liter. At higher concentrations a relatively slow decrease in
bacterial numbers was observed, and 99% killing of the in-
oculum was obtained after exposure to 32 mg/liter EMB for 21
days. The bactericidal killing capacity of EMB was decreased
when the MAC was in the late log phase of growth. At a
concentration of 64 mg/liter EMB 90% killing of the inoculum
was obtained after exposure of 10 days (data not shown).
RIF exhibited bactericidal activity on early-log-phase MAC
which effect was concentration-dependent as well as time-de-
pendent (Fig. 3A and B, Table 1). A concentration of 4 mg/
liter resulted in inhibition of visible growth. Initially bacterial
killing capacity of RIF was low,99% killing was not achieved
after 3 days of exposure but killing capacity increased with
time. After 10 days of exposure 99% killing was obtained at
4 mg/liter. Killing beyond 10 days of exposure was not ob-
served. Occurrence of resistant mycobacteria was excluded. A
bactericidal effect of RIF towards late-log-phase MAC was not
seen. RIF at 64 mg/liter effected 91% killing of the inoculum
within 10 days (data not shown).
AMK appeared highly and rapidly bactericidal against MAC
in the early log phase of growth (Fig. 4A and B, Table 1).
Inhibition of visible growth was obtained at 1 mg/liter. A con-
centration of only 2 mg/liter AMK effected99% killing of the
inoculum within 3 days. The bactericidal effect was concentra-
tion-dependent as well as time-dependent. However the high
bacterial killing capacity was not observed when MAC was in
the late log phase of growth. A concentration of 16 mg/liter or
64 mg/liter AMK resulted in 96% and 98% killing, respectively,
after 10 days of incubation (data not shown).
Exposure to MXF at a concentration of only 0.1 mg/liter
resulted in inhibition of visible growth of early-log-phase MAC
(Fig. 5A and B, Table 1). A concentration of only 1 mg/liter
MXF was needed to achieve  99% killing of the inoculum
within 10 days. The bactericidal effect was marginally concen-
tration-dependent within the therapeutic range, or time-de-
pendent. MXF also showed substantial killing capacity for
MAC in the late log phase of growth, 99% of the inoculum
was killed at 32 mg/liter within 10 days and at 16 mg/liter within
21 days (data not shown).
With respect to the aminoglycosides compared to AMK
STR was far less active whereas TOB and GEN were not active
at all at the concentrations tested (Table 1). Regarding the
quinolones compared to CIP and SPX, MXF exhibited higher
killing capacity towards MAC in the early log phase of growth
(Table 1) or the late log phase of growth (data not shown).
Among the agents effective in the therapy of tuberculosis
and known to be ineffective against MAC isolates, only INH
inhibited visible growth at high concentrations which are clin-
ically irrelevant, whereas PZA was not active at all at the
concentrations tested.
Time-kill studies of combinations of antimycobacterial
agents. It was investigated whether the combination of EMB to
CLR resulted in increased bactericidal activity against early-
log-phase MAC, and whether the addition of RIF, AMK, or
MXF to the CLR-EMB combination further reduced myco-
bacterial numbers (Table 2). All agents were used at the con-
centration that inhibited visible growth (Table 1). For CLR,
MIC as well as sub-MIC concentrations were used.
The addition of EMB to CLR did not substantially enhance
the bactericidal activity. Exposure to CLR alone at 4 mg/liter
or EMB alone at 16 mg/liter resulted in 86% killing and 83%
killing, respectively of the MAC population within 3 days,
whereas the combination of both agents killed 86% of MAC
within 3 days. After 10 days of exposure killing percentages
were 63%, 51%, and 81% for CLR, EMB and CLR-EMB,
respectively, and were not significantly different. In the pres-
ence of CLR at 2 mg/liter MAC numbers 10-fold increased
from 4.9  105 CFU/ml to 5.1  106 CFU/ml within 10 days.
With addition of EMB at 16 mg/liter, 77% killing of MAC was
achieved, whereas exposure to EMB alone resulted in 51%
killing. Addition of RIF or MXF to both CLR-EMB combi-
TABLE 1. Effect of antimycobacterial agents on Mycobacterium
avium complex in the early logarithmic phase of growtha
Antimycobacterial
agent
Lowest concn (mg/
liter) resulting in
99% killing at day:
Lowest concn (mg/liter)
resulting in inhibition of
visible growth at day 21
3 10 21
Clarithromycin 32 16 16 4
Ethambutol 64 64 32 16
Rifampin 64 4 8 4
Amikacin 2 2 2 1
Streptomycin 16 16 16 16
Tobramycin 16 64 64 64
Gentamicin 16 64 64 64
Moxifloxacin 8 1 0.5 0.1
Ciprofloxacin 64 32 2 0.25
Sparfloxacin 64 2 2 0.25
Isoniazid 64 64 64 64
Pyrazinamide 64 64 64 64
Amoxicillin-clavulanic
acid
64 64 64 64
a Mycobacterium avium strain 101 at 5  105 CFU/ml was exposed to the
antimycobacterial agent at twofold increasing concentrations (range, 0.05 to 64
mg/liter) for 21 days at 37°C. After 3, 10, or 21 days of exposure, quantitative
cultures were performed.
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FIG. 2. Mycobacterium avium strain 101 in the early logarithmic phase of growth was exposed to ethambutol at twofold increasing concentra-
tions for 21 days at 37°C. After 1, 2, 3, 10 or 21 days of exposure quantitative cultures were performed.
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FIG. 3. Mycobacterium avium strain 101 in the early logarithmic phase of growth was exposed to rifampin at twofold increasing concentrations
for 21 days at 37°C. After 1, 2, 3, 10 or 21 days of exposure quantitative cultures were performed.
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FIG. 4. Mycobacterium avium strain 101 in the early logarithmic phase of growth was exposed to amikacin at twofold increasing concentrations
for 21 days at 37°C. After 1, 2, 3, 10 or 21 days of exposure quantitative cultures were performed.
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FIG. 5. Mycobacterium avium strain 101 in the early logarithmic phase of growth was exposed to moxifloxacin at twofold increasing concen-
trations for 21 days at 37°C. After 1, 2, 3, 10 or 21 days of exposure quantitative cultures were performed.
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nations resulted in slightly increased killing of MAC. However
compared to either exposure alone a decrease in mycobacterial
numbers of 1 log was never obtained. The most effective com-
bination was AMK added to CLR 2 mg/liter and EMB 16
mg/liter, resulting in a tenfold enhanced bactericidal activity
within 3 days of exposure compared to AMK or CLR-EMB
(P  0.01).
The addition of the beta-lactam AMC to AMK significantly
enhanced the antimicrobial activity as shown in Table 3. AMC
alone at 4 mg/liter or 16 mg/liter only inhibited early-log-phase
MAC growth. In the presence of AMK at 0.5 mg/liter alone
MAC numbers increased from 5  105/ml to 2.5  107/ml
within 10 days. Exposure of MAC to a combination of AMK
0.5 mg/liter and AMC 4 mg/liter or 16 mg/liter resulted in 98%
killing within 10 days (P  0.01). After exposure to AMK 1
mg/liter alone MAC numbers were reduced about 9-fold
within 10 days, whereas addition of AMC at 4 mg/liter or 16
mg/liter to AMK 1 mg/liter resulted in enhanced killing, being
99% and 99.9%, respectively after 10 days of exposure (P 
0.01).
DISCUSSION
The antimicrobial treatment of MAC infections, particularly
in patients with AIDS, is difficult. This is in part due to the
severely depressed state of host defense mechanisms in these
patients, resulting in reduced macrophage antimicrobial capac-
ity (4). In addition, the variability of MAC isolates in suscep-
tibility to most antimycobacterial agents, except for macro-
lides, is high (29, 25, 26).
A number of agents have been suggested for treatment of
MAC infections (3). Mostly macrolide-containing multidrug
treatment regimens are applied (3, 6, 9, 13, 15, 28, 45, 48). In
clinical studies the macrolide CLR showed high efficacy against
disseminated MAC infections in patients with AIDS or non-
AIDS patients with localized pulmonary disease (2, 4, 9, 11,
25). The macrolides (particularly CLR) are the only antimi-
crobial agents for which a correlation between in vitro suscep-
tibility tests (broth dilution) for MAC and clinical response has
been demonstrated in controlled clinical trials (25, 26). Em-
pirical regimens in the treatment of MAC infections are rec-
ommended (3, 30).
As clinical studies show a high risk for relapse and emer-
gence of resistant isolates during monotherapy with macro-
lides, combinations of agents are used primarily in order to
reduce the incidence of macrolide resistance. However, uncer-
tainty persists regarding the optimal drugs that should accom-
pany a macrolide (6). EMB is recommended as a second drug
(31). It has been shown in vitro (34) as well as in vivo in a
mouse model of disseminated MAC infection (8) that the
combination of CLR and EMB is effective at reducing the
incidence of CLR resistant mutants. However, the addition of
EMB appeared to have no significant effect on the reduction of
bacterial numbers (19). Also, a clinical study of Dube et al.
shows that the addition of EMB to a CLR regimen results in a
reduction in the development of resistance but does not en-
hance clearance rates of MAC from the blood (15).
Rifamycins, including RIF, have the best potential as a third
agent, although their role is not fully clarified. In addition,
RIF, by inducing the hepatic cytochrome P450 pathways, re-
sults in substantial reductions in the bioavailability of CLR (37,
52). For severe cases of MAC disease, other antimycobacterial
drugs such as quinolones and aminoglycosides are suggested.
The potential of fluoroquinolones or aminoglycosides is of
considerable interest because of the proven clinical activity of
these agents against other mycobacterial species, including My-
cobacterium tuberculosis (1, 48, 14).
Quinolones including CIP, SPX, and MXF, have been used
in relatively effective MAC multidrug treatment regimens (7,
13, 45, 1). MXF particularly had significant anti-MAC activity
TABLE 2. Effect of combinations of antimycobacterial agents on
Mycobacterium avium complex in the early
logarithmic phase of growtha
Concn (mg/liter) Log CFU/mlat day:
Clarithromycin Ethambutol Rifampin Amikacin Moxifloxacin 0 3 10
0 0 0 0 0 5.7 7.6 9.1
2 5.2 6.7
2 16 4.5 5.0
2 4 4.4 3.0
2 1 4.3 3.9
2 0.1 5.1 6.6
2 16 4 3.9 2.5
2 16 1 3.6 4.9
2 16 0.1 4.4 5.0
4 4.8 5.3
4 16 4.8 5.0
4 4 4.5 3.0
4 1 4.5 4.3
4 0.1 4.7 4.8
4 16 4 4.5 2.7
4 16 1 4.4 4.3
4 16 0.1 4.6 5.1
16 4.9 5.4
4 4.5 3.1
1 4.7 4.4
0.1 6.1 6.9
a Mycobacterium avium strain 101 at 5  105 CFU/ml was exposed to the
antimycobacterial agent for 10 days at 37°C. After 3 or 10 days of exposure,
quantitative cultures were performed.
TABLE 3. Effect of combination of antimycobacterial agents on
Mycobacterium avium complex in the early
logarithmic phase of growtha
Concn (mg/liter) Log CFU/mL at day:
Amikacin Amoxicillin-clavulanic acid 0 3 10
0 0 5.7 7.8 9.3
0.5 4 3.9 3.9
0.5 16 4.0 3.9
0.5 6.2 7.4
4 5.7 6.0
16 5.6 5.5
1.0 4.8 4.8
1.0 4 3.9 3.5
1.0 16 2.9 2.7
a See Table 2, footnote a.
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in beige mice (7). Still, the antimicrobial activity of each of the
quinolones is not yet fully understood. The aminoglycosides
AMK and STR are highly active and reduce the incidence of
resistance in macrolide-containing regimens in animal models
of MAC (33). Aminoglycosides have been used in clinical stud-
ies in successful treatment regimens, whereas other investiga-
tors failed to show a beneficial effect of aminoglycosides (36).
However, Fattorini et al. demonstrated in in vitro assays that
AMK significantly improved the activity of the CLR-EMB
combination (17). The potential risks and benefits of treatment
with aminoglycosides should be weighed carefully. These
agents should be considered especially as part of short-term
induction therapy in view of toxicity observed with long-term
administration.
Although the macrolides are recognized to be the most
active of the drugs available for MAC treatment, important
questions remain in defining optimal treatment. The relative
contribution in terms of antimicrobial activity of each of the
components in the multidrug regimen is not clear. Some pa-
tients receiving multidrug macrolide-containing regimens who
initially respond to therapy develop relapse of infection, which
is often the result of insufficient antimicrobial activity (assum-
ing adherence to the drug regimen and no further decline of
the host’s cellular immune response).
The MAC strain 101 used in the present study, originally
isolated from the blood of an AIDS patient with disseminated
MAC infection, appeared CLR susceptible following the
breakpoints for determining susceptibility and resistance ac-
cording to the NCCLS guidelines (35, 53). The data show that
five relevant antimycobacterial agents, CLR, EMB, RIF,
AMK, and MXF, all inhibited mycobacterial growth at clini-
cally relevant concentrations but differed with respect to their
bactericidal activity during 21 days of exposure of the early-
log-phase MAC. At the end of the 21-day incubation period,
compared to the concentrations resulting in growth inhibition,
the concentrations needed to achieve a bactericidal effect
(99% killing) were always twofold or fourfold higher. CLR,
RIF, and AMK particularly showed concentration-dependent
killing.
However, with respect to the bacterial killing rate, the agents
differed markedly. For AMK the high bactericidal activity
(99% killing) observed after 21 days was already obtained
after 3 days of exposure. In contrast, for MXF the concentra-
tion needed to achieve bactericidal activity within 3 days was
16-fold higher compared to the concentration needed at 21
days of exposure. At the end of the incubation period of 21
days MXF was superior over AMK, whereas after 3 days of
incubation AMK appeared superior over MXF. Actually, the
high killing rate of AMK is unique, and in this respect AMK is
superior to MXF as well as CLR, EMB, and RIF. RIF showed
concentration-dependent as well as time-dependent bacteri-
cidal activity. Initially bacterial killing by RIF was low but
increased with time. The killing rate of RIF was higher com-
pared to that of CLR that showed extremely low killing rate.
Whereas after 21 days of exposure RIF and CLR were similar
with respect to their bacteriostatic activity, both agents differ
regarding the rate of bactericidal activity. After 3 days of ex-
posure the bactericidal activity of RIF was less compared to
that of CLR, whereas after 21 days RIF appeared superior
over CLR. The low killing rate as seen for CLR was also
observed for EMB.
It can be concluded that the antimicrobial agents differ with
respect to time-dependent bacterial killing capacity. After
long-term exposure of 21 days the comparative bactericidal
capacity is highest for MXF, followed by AMK, RIF, CLR, and
EMB, respectively. After short-term exposure of 3 days the
comparative bactericidal capacity is highest for AMK, followed
by MXF, CLR, and RIF or EMB. The rate of bacterial killing
may have more clinical significance than the degree of killing,
as in vivo after administration of the agents exposure to clin-
ically achievable concentrations lasts for only a limited period
of time. In addition, a rapid decrease in mycobacterial load is
needed for therapeutic efficacy and also may result in a re-
duced risk of development of drug resistance. In this respect
AMK seems to be superior, as it was the only agent that was
rapidly bactericidal at relatively low concentrations which are
far below the achievable plasma concentrations. These are
important parameters which may compensate in part for the
low intracellular penetrating capability of this agent.
RIF and MXF are bactericidal at concentrations below the
concentrations achievable in plasma and tissues and inside
infected cells. CLR inhibited bacterial growth at plasma con-
centrations attainable in vivo. Bacterial killing was only
achieved at relatively high concentrations, and the killing rate
of CLR is extremely low. As CLR concentrates intracellularly
in macrophages and achieves excellent tissue penetration, it is
bactericidal in mice and humans. Compared to CLR, higher
concentrations of EMB were needed to obtain a bacteriostatic
or bactericidal effect, which are far above the concentrations
achievable in vivo. The relatively high concentration of EMB
needed to obtain growth inhibition is within the range of MICs
of EMB for most MAC isolates (20 to 32 mg/liter). EMB is
considered bacteriostatic, and its principal role has been as a
companion drug to prevent macrolide resistance.
Compared to the other aminoglycosides AMK appeared su-
perior over STR, TOB, and GEN, which were active at only
relatively high concentrations. This finding is in agreement
with the general observation that AMK is the most active
aminoglycoside against the nontuberculous mycobacteria (20).
Regarding the quinolones, MXF, particularly during the first 3
days of exposure, appeared superior over SPX and CIP. After
21 days of exposure, SPX and CIP showed similar bactericidal
activity, but in terms of killing rate SPX is superior over CIP.
The other agents investigated, INH, PZA, and AMC, were far
less active. PZA was not bactericidal at all at the concentra-
tions tested, whereas INH and AMC were bactericidal only at
high concentrations that are not clinically relevant. It is gen-
erally known that these agents are not useful for treatment of
MAC infections.
Based on the results of bacteriostatic capacity in terms of
growth inhibition, CLR, RIF, AMK, and MXF all show sub-
stantial activity. According to the thresholds for interpretation
of growth inhibition (23), MAC strain 101 is considered “sus-
ceptible” to these agents. However, the present study demon-
strates that the assay of time-dependent bactericidal capacity is
more discriminative. The data show that these agents differ
substantially with respect to their bactericidal capacity, partic-
ularly the killing rate, demonstrating a superior and rapid
killing activity of AMK and high killing activity of MXF.
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In the treatment of MAC, combinations of antimycobacte-
rial agents are necessary to reduce the incidence of drug re-
sistance. It is not well understood whether their use also results
in improved efficacy in terms of enhanced eradication of my-
cobacteria. In the present study it was investigated whether
addition of a number of antimycobacterial agents to CLR
resulted in an increased level of bactericidal activity after 3 or
10 days of exposure in vitro against early-log-phase MAC.
Significant enhancement of activity of CLR by combination
with EMB could not be demonstrated. Only an additive effect
has been shown. The addition of RIF or MXF as a third agent
to the CLR-EMB combination did not significantly promote
enhanced bacterial killing. Although the three-drug combina-
tions resulted in higher bactericidal effect than any of the
exposures used alone, these combinations did never reach a 1
log further decrease in mycobacterial numbers. Only AMK had
a substantial effect by improving the activity of the combination
CLR-EMB tenfold within only 3 days of exposure. This is in
agreement with the findings of Fattorini et al., demonstrating
that the addition of AK made the combination of CLR-EMB
synergistic against a number of MAC strains in vitro (17).
Other studies investigating the in vitro activity of CLR in
combination with various antimycobacterial agents against
MAC show discrepancy in results. Besides claims by some
authors about a synergistic interaction between CLR in com-
bination with EMB (20), RIF (49, 47), EMB and RIF (41),
AMK (38), or various quinolones (38), only additive effects
have been observed (20, 32). In addition, antagonism has been
reported between CLR in combination with AMK (17) or
quinolones (49). As the studies on the in vitro activities of CLR
in two-drug combinations or three-drug combinations against
MAC are controversial, these studies do not clearly provide
insight into the rational design of combinations of agents with
potent therapeutic activity.
Beta-lactam activity against mycobacteria has been de-
scribed. However, the doses required to obtain efficacy in in-
fection are not feasible. Synergistic activity of aminoglycoside–
beta-lactam combinations towards bacterial strains is well
known but was not investigated for mycobacteria. In the
present study the addition of the beta-lactamase-stable AMC
to AMK resulted in a higher level of MAC killing. In view of
the low intracellular penetrating capability of aminoglycosides
and beta-lactams, the clinical relevance of this finding with
respect to intracellular MAC is questionable. However, as a
result of their high antimicrobial activity, an aminoglycoside
alone or in combination with a beta-lactam may be efficacious
in eliminating MAC organisms which are growing extracellu-
larly in the cavitating lesions in advanced stages of MAC in-
fection.
There are many factors influencing the activity of antibiotics
in vivo. Besides the antibiotic susceptibility of the infectious
agent, the concentration profile of the antibiotic in serum,
other body fluids, and tissues, and at the site of infection in
relation to the dosing regimen is of importance. With respect
to mycobacterial infections, antimicrobial activity against my-
cobacteria at the low growth rate is also an important deter-
minant for therapeutic efficacy in view of the low metabolic
activity of mycobacteria residing in tissues in the dormant
state. The data from the present study show that, towards
MAC that are not actively growing, only the quinolones exhib-
ited bactericidal activity, although the absolute killing of these
was substantially less compared to that of actively growing
MAC. Even AMK, which was highly bactericidal against ac-
tively growing MAC, appeared not to be effective against MAC
at the low growth rate. Whether this superior activity of quin-
olones for dormant Mycobacterium avium implies that quino-
lones should be used in the first line regimen for Mycobacte-
rium avium disease will have to be clinically evaluated.
REFERENCES
1. Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolo-
nes for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25:1213–
1221.
2. American Thoracic Society. 1997. Diagnosis and treatment of disease caused
by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1–
S25.
3. Amsden, G. W., C. A. Peloquin, and S. E. Berning. 1997. The role of
advanced generation macrolides in the prophylaxis and treatment of Myco-
bacterium avium complex (MAC) infections. Drugs 54:69–80.
4. Benson, C. A. 1996. Treatment of disseminated Mycobacterium avium com-
plex disease: a clinician’s perspective. Res. Microbiol. 147:16–24.
5. Benson, C. A. 1998. Disseminated Mycobacterium avium complex infection:
implications of recent clinical trials on prophylaxis and treatment. AIDS
Clin. Rev. 1998:271–287.
6. Benson, C. A., P. L. Williams, J. S. Currier, F. Holland, L. F. Mahon, R. R.
MacGregor, C. B. Inderlied, C. Flexner, J. Neidig, R. Chaisson, G. F. No-
tario, R. Hafner, and the AIDS Clinical Trial Group 223 Protocol Team.
2003. A prospective randomized trial examinig the efficacy and safety of
clarithromycin in combination with ethambutol, rifabutin, or both for the
treatment of disseminated Mycobacterium avium complex disease in persons
with acquired immunodeficiency syndrome. Clin. Infect. Dis. 37:1234–1243.
7. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Petrofsky, P. Aralar, M.
Wu, and L. S. Young. 2001. Activity of moxifloxacin by itself and in combi-
nation with ethambutol, rifabutin, and azithromycin in vitro and in vivo
against Mycobacterium avium. Antimicrob. Agents Chemother. 45:217–222.
8. Bermudez, L. E., K. A. Nash, M. Petrofsky, L. S. Young, and C. B. Inderlied.
1996. Effect of ethambutol on emergence of clarithromycin-resistant Myco-
bacterium avium complex in the beige mouse model. J. Infect. Dis. 174:1218–
1222.
9. Chaisson, R. E., C. A. Benson, M. P. Dube´, L. B. Heifets, J. A. Korvick, S.
Elkin, T. Smith, J. C. Craft, and F. R. Sattler. 1994. Clarithromycin therapy
for Mycobacterium avium complex bacteremia in patients with AIDS. Ann.
Intern. Med. 121:905–911.
10. Chan, I. S. F., J. D. Neaton, L. D. Saravolatz, L. R. Crane, and J. Oster-
berger. 1995. Frequencies of opportunistic diseases prior to death among
HIV-infected persons. AIDS 9:1145–1151.
11. Dautzenberg, B. 1994. Clinical trials of disseminated Mycobacterium avium
therapy: lessons to take home. Res. Microbiol. 145:197–206.
12. Davies, P. D. 2003. Recent developments in the treatment of tuberculosis.
Expert Opin. Investig. Drugs 12:1297–1312.
13. De Lalla, F., R. Maserati, P. Scarpellini, P. Marone, R. Nicolin, F. Caccamo,
and R. Rigoli. 1992. Clarithromycin-ciprofloxacin-amikacin for therapy of
Mycobacterium avium–Mycobacterium intracellulare bacteremia in patients
with AIDS. Antimicrob. Agents Chemother. 36:1567–1569.
14. Donald, P. R., F. A. Sirgel, A. Venter, E. Smit, D. P. Parkin, B.W. van de Wal,
and D. A. Mitchison. 2001. The early bactericidal activity of amikacin in
pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 5:533–538.
15. Dube, M. P., F. R. Sattler, F. J. Torriani, D. See, D. V. Havlir, C. A. Kemper,
M. G. Dezfuli, S. A. Bozzette, A. E. Bartok, J. M. Leedom, J. G. Tilles, and
J. A. McCutchan. 1997. A randomized evaluation of ethambutol for preven-
tion of relapse and drug resistance during treatment of Mycobacterium avium
complex bacteremia with clarithromycin-based combination therapy. Cali-
fornia Collaborative Treatment Group. J. Infect. Dis. 176:1225–1232.
16. Espinal, M. A. 2003. The global situation of MDR-TB. Tuberculosis 83:44–
51.
17. Fattorini, L., B. Li, C. Piersimoni, E. Tortoli, Y. Xiao, C. Santoro, M. L.
Ricci, and G. Orefici. 1995. In vitro and ex vivo activities of antimicrobial
agents used in combination with clarithromycin, with or without amikacin,
against Mycobacterium avium. Antimicrob. Agents Chemother. 39:680–685.
18. Fre´hel, C., C. Offredo, and C. de Chastellier. 1997. The phagosomal envi-
ronment protects virulent Mycobacterium avium from killing and destruction
by clarithromycin. Infect. Immun. 65:2792–2802.
19. Furney, S. K., P. S. Skinner, J. Farrer, and I. M. Orme. 1995. Activities of
rifabutin, clarithromycin, and ethambutol against two virulent strains of
Mycobacterium avium in a mouse model. Antimicrob. Agents Chemother.
39:786–789.
20. Gevaudan, M. J., C. Bollet, M. N. Mallet, and P. de Micco. 1993. In-vitro
evaluation of clarithromycin, temafloxacin, and ethambutol in combination
VOL. 49, 2005 ANTIMYCOBACTERIAL AGENTS 2397
against Mycobacterium avium complex. J. Antimicrob. Chemother. 31:725–
730.
21. Grosset, J., and B. Ji. 1997. Prevention of the selection of clarithromycin-
resistant Mycobacterium avium-intracellulare complex. Drugs 54(Suppl. 2):
23–27.
22. Heifets, L. B. 1991. Dilemmas and realities in drug susceptibility testing of M.
avium–M. intracellulare and other slowly growing nontuberculous mycobac-
teria, p. 123–146. In L. B. Heifets (ed.), Drug susceptibility in the chemo-
therapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
23. Heifets, L. B. 1994. Quantitative cultures and drug susceptibility testing of
Mycobacterium avium clinical isolates before and during the antimicrobial
therapy. Res. Microbiol. 145:188–196.
24. Heifets, L. B. 1996. Drug susceptibility testing. Clin. Mycobacteriol. 16:641–
656.
25. Heifets, L. 1996. Clarithromycin against Mycobacterium avium complex in-
fection. Tuberc. Lung Dis. 77:19–26.
26. Heifets, L. 1996. Susceptibility testing of Mycobacterium avium complex
isolates. Antimicrob. Agents Chemother. 40:1759–1767.
27. Heifets, L. B., and M. D. Iseman. 1991. Individualized therapy versus stan-
dard regimens in the treatment of Mycobacterium avium infections. Am. Rev.
Respir. Dis. 144:1–2.
28. Heifets, L., N. Mor, and J. Vanderkolk. 1993. Mycobacterium avium strains
resistant to clarithromycin and azithromycin. Antimicrob. Agents Che-
mother. 37:2364–2370.
29. Inderlied, C. B., C. A. Kemper, and L. E. M. Bermudez. 1993. The Myco-
bacterium avium complex. Clin. Microbiol. Rev. 6:266–310.
30. Iseman, M. D. 2002. Medical management of pulmonary disease caused by
Mycobacterium avium complex. Clin. Chest Med. 23:633–641.
31. Kaplau, J. E., H. Masure, and K. K. Holmes. 2002. Guidelines for preventing
opportunistic infections among HIV-infected persons-2002: recommenda-
tions of the US Public Health Service and the Infectious Diseases Society of
America. Morb. Mortal. Wkly Rep. 51:1–52.
32. Kent, R. J., M. Bakhtiar, and D. C. Shanson. 1992. The in-vitro bactericidal
activities of combinations of antimicrobial agents against clinical isolates of
Mycobacterium avium-intracellulare. J. Antimicrob. Chemother. 30:643–650.
33. Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1995. Selection of
clarithromycin-resistant Mycobacterium avium complex during combined
therapy using the beige mouse model. Antimicrob. Agents Chemother. 39:
608–612.
34. Nash, K. A. 2001. Effect of drug concentration on emergence of macrolide
resistance in Mycobacterium avium. Antimicrob. Agents Chemother.
45:1607–1614.
35. National Committee for Clinical Laboratory Standards. 2000. Susceptibility
testing of mycobacteria, Nocardia, and other aerobic actinomycetes; tenta-
tive standard M24–T2, 2nd ed. National Committee for Clinical Laboratory
Standards, Wayne, PA.
36. Parenti, D. M., P. L. Williams, R. Hafner, M. R. Jacobs, P. Hojczyk, T. M.
Hooton, T. W. Barber, G. Simpson, C. van der Horst, J. Currier, W. G.
Powderly, M. Limjoco, and J. J. Ellner. 1998. A phase II/III trial of antimi-
crobial therapy with or without amikacin in the treatment of disseminated
Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical
Trials Group Protocol 135 Study Team. AIDS 12:2439–2446.
37. Peloquin, C. A., and S. E. Berning. 1996. Evaluation of the drug interaction
between clarithromycin and rifampin. J. Infect. Dis. Pharmacother. 2:19–35.
38. Piersimoni, C., E. Tortoli, M. T. Mascellino, C. Passerini Tosi, G. Sbaraglia,
F. Mandler, F. Bistoni, S. Bornigia, G. De Sio, A. Goglio, E. Iona, M. B.
Pasticci, and M. T. Simonetti. 1995. Activity of seven antimicrobial agents,
alone and in combination, against AIDS-associated isolates of Mycobacte-
rium avium complex. J. Antimicrob. Chemother. 36:497–502.
39. Quy, H. T., N. T. Lan, M. W. Borgdorff, J. Grosset, P. D. Link, L. B. Tung,
D. van Soolingen, M. Raviglione, N. V. Co, and J. Broekmans. 2003. Drug
resistance among failure and relapse cases of tuberculosis: is the standard
re-treatment regimen adequate. Int. J. Tuberc. Lung Dis. 7:607–608.
40. Rastogi, N., K. S. Goh, A. Bryskier, and A. Devallois. 1996. Spectrum of
activity of levofloxacin against nontuberculous mycobacteria and its activity
against the Mycobacterium avium complex in combination with ethambutol,
rifampin, roxithromycin, amikacin and clofazimine. Antimicrob. Agents Che-
mother. 40:2483–2487.
41. Rastogi, N., and V. Labrousse. 1991. Extracellular and intracellular activities
of clarithromycin used alone and in association with ethambutol and ri-
fampin against Mycobacterium avium complex. Antimicrob. Agents Che-
mother. 35:462–470.
42. Raviglione, M. C. 2003. The TB epidemic from 1992 to 2002. Tuberculosis
83:4–14.
43. Samuel, R., R. L. Bettiker, and B. Suh. 2002. AIDS related opportunistic
infections, going but not gone. Arch. Pharm. Res. 25:215–228.
44. Schiavano, G. F., A. G. Celeste, L. Salvaggio, M. Sisti, and G. Brandi. 2001.
Efficacy of macrolides used in combination with ethambutol, with or without
other drugs, against Mycobacterium avium within human macrophages. Int. J.
Antimicrob. Agents 18:525–530.
45. Shafran, S. D., J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley,
I. W. Fong, M. J. Gill, A. R. Rachlis, R. G. Lalonde, M. M. Fanning, and
C. M. Tsoukas. 1996. A comparison of two regimens for the treatment of
Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol,
and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxa-
cin. N. Engl. J. Med. 335:377–383.
46. Shafran, S. D., J. A. Talbot, S. Chomye, E. Davison, J. Singer, P. Phillips, I.
Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, and R. G. Lalonde
for the Canadian HIV Trials Network Protocol 010 Study Group. 1998. Does
in vitro susceptibility to rifabutin and ethambutol predict the response to
treatment of Mycobacterium avium complex bacteremia with rifabutin,
ethambutol, and clarithromycin? Clin. Infect. Dis. 27:1401–1405.
47. Stauffer, F., O. Do¨rtbudak, and E. Lahonik. 1991. In vitro testing of clar-
ithromycin in combination with ethambutol and rifampin against Mycobac-
terium avium complex. Infection 19:343–345.
48. Tomioka, H. 2000. Prospects for development of new antimycobacterial
drugs. J. Infect. Chemother. 6:8–20.
49. Tomioka, H., C. Sano, K. Sato, and T. Shimizu. 2002. Antimicrobial activities
of clarithromycin, gatifloxacin and sitafloxacin, in combination with various
antimycobacterial drugs against extracellular and intramacrophage Mycobac-
terium avium complex. Int. J. Antimicrob. Agents. 19:139–145.
50. Tomioka, H., K. Sato, H. Kajitani, T. Akaki, and S. Shishido. 2000. Com-
parative antimicrobial activities of the newly synthesized quinolone WQ-
3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium
tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Che-
mother. 44:283–286.
51. Wallace, R. J. Jr. 2000. Antimycobacterial agents, p. 436–447. In G. L.
Mandell, J. E. Bennet, and R. Dolin (ed.), Principles and practice of infec-
tious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA.
52. Wallace, R. J. Jr, B. A. Brown, D. E. Griffith, W. Girard, and K. Tanaka.
1995. Reduced serum levels of clarithromycin in patients treated with mul-
tidrug regimens including rifampin or rifabutin for Mycobacterium avium-
Mycobacterium intracellulare infection. J. Infect. Dis. 171:747–750.
53. Woods, G. L., N. Williams-Bouyer, R. J. Wallace, B. A. Brown-Elliott, F. G.
Witebsky, P. S. Conville, M. Plaunt, G. Hall, P. Aralar, and C. Inderlied.
2003. Multisite reproducibility of results obtained by two broth dilution
methods for susceptibility testing of Mycobacterium avium complex. J. Clin.
Microbiol. 41:627–631.
54. Young, L. S., and L. E. Bermudez. 2001. Perspective on animal models:
chronic intracellular infections. Clin. Infect. Dis. 33(Suppl. 3):S221–S226.
55. Zimmer, B., D. R. DeYoung, and G. D. Roberts. 1982. In vitro synergistic
activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin
against Mycobacterium avium-intracellulare complex. Antimicrob. Agents
Chemother. 22:148–150.
2398 BAKKER-WOUDENBERG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
